Anti-tumor Activity of Toll-Like Receptor 7 Agonists

TRAF6 is a critical factor in fish immune response to virus infection

(2017) Jingguang Wei et al.   FISH & SHELLFISH IMMUNOLOGY

Cloning and functional characterization of IRAK4 in large yellow croaker ( Larimichthys crocea ) that associates with MyD88 but impairs NF-κB activation

(2017) Peng Fei Zou et al.   FISH & SHELLFISH IMMUNOLOGY

The TLR3 Agonist Inhibit Drug Efflux and Sequentially Consolidates Low-Dose Cisplatin-Based Chemoimmunotherapy while Reducing Side Effects

(2017) Liang Ding et al.   MOLECULAR CANCER THERAPEUTICS

Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases

(2017) Lupe G. Salazar et al.   JAMA Oncology

TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells

(2016) Rujuta A. Bam et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases

(2016) Ileana S. Mauldin et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Poly(I:C) potentiates Bacillus Calmette–Guérin immunotherapy for bladder cancer

(2016) Cherifa Ayari et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

TLR7 Structure: Cut in Z-Loop

(2016) Kazuhiko Maeda et al.   IMMUNITY

Imiquimod activates p53-dependent apoptosis in a human basal cell carcinoma cell line

(2016) Shi-Wei Huang et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

A video-based educational pilot for basal cell carcinoma (BCC) treatment: A randomized controlled trial

(2016) Elyse M. Love et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Beneficial effect of low-level laser therapy in acute lung injury after i-I/R is dependent on the secretion of IL-10 and independent of the TLR/MyD88 signaling

(2016) J. L. Carvalho et al.   LASERS IN MEDICAL SCIENCE

Toll-like receptors signaling: A complex network for NF-κB activation in B-cell lymphoid malignancies

(2016) Stavroula Ntoufa et al.   SEMINARS IN CANCER BIOLOGY

Inhibition of IL-1R1/MyD88 signalling promotes mesenchymal stem cell-driven tissue regeneration

(2016) Mikaël M. Martino et al.   Nature Communications

Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy

(2016) Simon J. Dovedi et al.   Oncotarget

A Standardized Chemically Modified Curcuma longa Extract Modulates IRAK-MAPK Signaling in Inflammation and Potentiates Cytotoxicity

(2016) Minakshi Rana et al.   Frontiers in Pharmacology

A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice

(2016) Gabriela Maria Wiedemann et al.   OncoImmunology

Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma

(2015) A. H. Rook et al.   BLOOD

TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice

(2015) Erina Koga-Yamakawa et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice

(2015) Hiroyasu Ito et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial

(2015) Renata Ursu et al.   CANCER SCIENCE

Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model

(2015) Hiroyasu Ito et al.   IMMUNOLOGY

Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma

(2015) Jiang Zhu et al.   Journal of Hematology & Oncology

Toll-like receptor 7/8 agonist, R848, exhibits antitumoral effects in a breast cancer model

(2015) TAO YIN et al.   Molecular Medicine Reports

Activation of Toll-like receptor 7 inhibits the proliferation and migration, and induces the apoptosis of pancreatic cancer cells

(2015) BING-BING ZOU et al.   Molecular Medicine Reports

Antitumor activity of a novel small molecule TLR7 agonist via immune response induction and tumor microenvironment modulation

(2015) YUWEN DIAO et al.   ONCOLOGY REPORTS

Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects

(2015) Xiao-Dong Wang   WORLD JOURNAL OF GASTROENTEROLOGY

The TLR7 agonist induces tumor regression both by promoting CD4+T cells proliferation and by reversing T regulatory cell-mediated suppression via dendritic cells

(2015) Chenchen Wang et al.   Oncotarget

Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors

(2015) Sebastian Schölch et al.   Oncotarget

Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma

(2015) R. L. Sabado et al.   Cancer Immunology Research

Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment

(2015) Valentino Le Noci et al.   OncoImmunology

Toll-like Receptor 3 Regulates Angiogenesis and Apoptosis in Prostate Cancer Cell Lines through Hypoxia-Inducible Factor 1α

(2015) Alessio Paone et al.   NEOPLASIA

The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma

(2014) Pallab Pradhan et al.   BIOMATERIALS

Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy

(2014) David A. Smith et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phosphorothioate-modified CpG oligodeoxynucleotide (CpG ODN) induces apoptosis of human hepatocellular carcinoma cells independent of TLR9

(2014) Yuyi Zhang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma

(2014) D. W. Northfelt et al.   CLINICAL CANCER RESEARCH

A novel systemically administered toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models

(2014) Amy L. Adlard et al.   INTERNATIONAL JOURNAL OF CANCER

TLR Ligands in the Local Treatment of Established Intracerebral Murine Gliomas

(2014) O. M. Grauer et al.   JOURNAL OF IMMUNOLOGY

Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation

(2014) Manisha Singh et al.   JOURNAL OF IMMUNOLOGY

The role of TLR8 signaling in acute myeloid leukemia differentiation

(2014) J J Ignatz-Hoover et al.   LEUKEMIA

A Flagellin-Derived Toll-Like Receptor 5 Agonist Stimulates Cytotoxic Lymphocyte-Mediated Tumor Immunity

(2014) Nicholas D. Leigh et al.   PLoS One

GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees

(2013) Robert E. Lanford et al.   GASTROENTEROLOGY

Induction of pro-inflammatory cytokine production in thymocytes by the immune response modifiers Imiquimod and Gardiquimod™

(2013) Andreas Weber et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Poly(I:C) exhibits an anti-cancer effect in human gastric adenocarcinoma cells which is dependent on RLRs

(2013) Jing Qu et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

In vitro and in vivo growth inhibition of prostate cancer by the small molecule imiquimod

(2013) JU-HEE HAN et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Inhibitory effect of dsRNA TLR3 agonist in a rat hepatocellular carcinoma model

(2013) YU-YIN XU et al.   Molecular Medicine Reports

IL-27 Enhances the Expression of TRAIL and TLR3 in Human Melanomas and Inhibits Their Tumor Growth in Cooperation with a TLR3 Agonist Poly(I:C) Partly in a TRAIL-Dependent Manner

(2013) Yukino Chiba et al.   PLoS One

Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RAR  and tumor regression

(2013) R. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Trial Watch

(2013) Erika Vacchelli et al.   OncoImmunology

Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies

(2012) Brenda J. Weigel et al.   AMERICAN JOURNAL OF HEMATOLOGY

Toll-like Receptor 5 Agonist Inhibition of Growth of A549 Lung Cancer Cells in Vivo in a Myd88 Dependent Manner

(2012) Shi-Xiang Zhou et al.   Asian Pacific Journal of Cancer Prevention

Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll-like receptor 7 agonists with high water solubility

(2012) Tomoaki Nakamura et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma

(2012) S. J. Dovedi et al.   BLOOD

Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer

(2012) S. Adams et al.   CLINICAL CANCER RESEARCH

Synergy of Topical Toll-like Receptor 7 Agonist with Radiation and Low-Dose Cyclophosphamide in a Mouse Model of Cutaneous Breast Cancer

(2012) M. Z. Dewan et al.   CLINICAL CANCER RESEARCH

Intratracheal and oral administration of SM-276001: A selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer

(2012) Erina Koga-Yamakawa et al.   INTERNATIONAL JOURNAL OF CANCER

Pharmacokinetics of Daily Self-Application of Imiquimod 3.75% Cream in Adult Patients With External Anogenital Warts

(2012) Jason Wu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Toll-like receptor 7 agonist, Imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis

(2012) Mee-Young Ahn et al.   JOURNAL OF ORAL PATHOLOGY & MEDICINE

TLR3 dsRNA agonist inhibits growth and invasion of HepG2.2.15 HCC cells

(2012) Li Chen   ONCOLOGY REPORTS

Trial Watch

(2012) Lorenzo Galluzzi et al.   OncoImmunology

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy

(2012) Erika Vacchelli et al.   OncoImmunology

Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment

(2011) Shangzi Wang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers

(2011) R. Rosa et al.   CLINICAL CANCER RESEARCH

Intratumoral Administration of TLR4 Agonist Absorbed into a Cellular Vector Improves Antitumor Responses

(2011) M. B. Davis et al.   CLINICAL CANCER RESEARCH

Toll-like receptor 7 stimulation promotes autoimmune diabetes in the NOD mouse

(2011) A. S. Lee et al.   DIABETOLOGIA

TLR1/TLR2 Agonist Induces Tumor Regression by Reciprocal Modulation of Effector and Regulatory T Cells

(2011) Y. Zhang et al.   JOURNAL OF IMMUNOLOGY

Immunomodulation by Imiquimod in Patients with High-Risk Primary Melanoma

(2011) Rupa Narayan et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers

(2010) Melissa A. Geller et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice

(2010) Fang Ma et al.   Cellular & Molecular Immunology

Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist

(2010) Thanh Nhan Nguyen Pham et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

The TAK1–TRAF6 signalling pathway

(2010) Marene Landström   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Intravesical Toll-like receptor 7 agonist R-837: Optimization of its formulation in an orthotopic mouse model of bladder cancer

(2010) Tomoko Hayashi et al.   INTERNATIONAL JOURNAL OF UROLOGY

Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance

(2010) Julien Cherfils-Vicini et al.   JOURNAL OF CLINICAL INVESTIGATION

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

(2010) Joshua D. Brody et al.   JOURNAL OF CLINICAL ONCOLOGY

TLR-signaling Networks

(2010) J. Brown et al.   JOURNAL OF DENTAL RESEARCH

Treatment Failure of a TLR-7 Agonist Occurs Due to Self-Regulation of Acute Inflammation and Can Be Overcome by IL-10 Blockade

(2010) H. Lu et al.   JOURNAL OF IMMUNOLOGY

A Critical Role for Mast Cells and Mast Cell-Derived IL-6 in TLR2-Mediated Inhibition of Tumor Growth

(2010) S. A. Oldford et al.   JOURNAL OF IMMUNOLOGY

Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma

(2010) Youn H. Kim et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Regression of Established AB1 Murine Mesothelioma Induced by Peritumoral Injections of CpG Oligodeoxynucleotide Either Alone or in Combination with Poly(I:C) and CD40 Ligand Plasmid DNA

(2010) Geoffrey W. Stone et al.   Journal of Thoracic Oncology

DAMPening Inflammation by Modulating TLR Signalling

(2010) A. M. Piccinini et al.   MEDIATORS OF INFLAMMATION

Targeting Toll-like receptors: emerging therapeutics?

(2010) Elizabeth J. Hennessy et al.   NATURE REVIEWS DRUG DISCOVERY

A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine

(2010) Antonella Conforti et al.   VACCINE

Synthesis and Immunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates

(2009) Michael Chan et al.   BIOCONJUGATE CHEMISTRY

Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

(2009) Jonathan W. Friedberg et al.   BRITISH JOURNAL OF HAEMATOLOGY

The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells

(2009) Evelien L. J. M. Smits et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Treatment of Mammary Carcinomas in HER-2 Transgenic Mice through Combination of Genetic Vaccine and an Agonist of Toll-Like Receptor 9

(2009) L. Aurisicchio et al.   CLINICAL CANCER RESEARCH

Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy

(2009) S. A. Broomfield et al.   JOURNAL OF IMMUNOLOGY

Reversal of Human Papillomavirus-Specific T Cell Immune Suppression through TLR Agonist Treatment of Langerhans Cells Exposed to Human Papillomavirus Type 16

(2009) L. M. Fahey et al.   JOURNAL OF IMMUNOLOGY

Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists

(2009) Svetlana Hamm et al.   Journal of Immunotoxicology

Imiquimod Enhances IFN-γ Production and Effector Function of T Cells Infiltrating Human Squamous Cell Carcinomas of the Skin

(2009) Susan J. Huang et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia

(2009) D E Spaner et al.   LEUKEMIA

TLR9 Signaling Promotes Tumor Progression of Human Lung Cancer Cell In Vivo

(2009) Tao Ren et al.   PATHOLOGY & ONCOLOGY RESEARCH

Nanoparticle-Delivered Multimeric Soluble CD40L DNA Combined with Toll-Like Receptor Agonists as a Treatment for Melanoma

(2009) Geoffrey W. Stone et al.   PLoS One

An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models

(2008) S Dharmapuri et al.   CANCER GENE THERAPY

NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model

(2008) Calin D. Dumitru et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

(2008) R. Dummer et al.   CLINICAL CANCER RESEARCH

TLR7 Agonist 852A Inhibition of Tumor Cell Proliferation Is Dependent on Plasmacytoid Dendritic Cells and Type I IFN

(2008) Jon R. Inglefield et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

TLR signaling by tumor and immune cells: a double-edged sword

(2008) B Huang et al.   ONCOGENE